Johnson & Johnson (JNJ)vsUtah Medical Products Inc (UTMD)
JNJ
Johnson & Johnson
$232.77
+1.07%
HEALTHCARE · Cap: $536.54B
UTMD
Utah Medical Products Inc
$67.65
-0.50%
HEALTHCARE · Cap: $221.10M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 256646% more annual revenue ($96.36B vs $37.53M). UTMD leads profitability with a 28.9% profit margin vs 21.8%. JNJ appears more attractively valued with a PEG of 2.91. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
UTMD
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Margin of Safety
-41.9%
Fair Value
$44.90
Current Price
$67.65
$22.75 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Strong operational efficiency at 34.5%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Revenue declined 10.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : UTMD
The strongest argument for UTMD centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 28.9% and operating margin at 34.5%.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : UTMD
The primary concerns for UTMD are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
JNJ profiles as a mature stock while UTMD is a declining play — different risk/reward profiles.
UTMD carries more volatility with a beta of 0.37 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 50/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Utah Medical Products Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The company is headquartered in Midvale, Utah.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?